BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that Christian S. Schade, President & Chief Executive Officer, will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 3:30 p.m. PT (6:30 p.m. ET).

A live webcast of the presentation can be accessed from "Events Calendar" in the News and Events section of the Aprea website at Link.

About Aprea Therapeutics, Inc.

Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is APR-246, a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).For more information, please visit the company website at www.aprea.com. 

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The forward-looking statements contained in this press release reflect Aprea’s current views with respect to future events, and Aprea does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Source:  Aprea Therapeutics

Corporate Contacts:

Scott M. Coiante
Sr. Vice President and Chief Financial Officer
617-463-9385

Gregory A. Korbel, Ph.D.
Vice President of Business Development
617-463-9385

Source: Aprea Therapeutics